Emerging evidence for the use of atypical antipsychotics in borderline personality disorder.
SourcePharmacopsychiatry, 38, 1, (2005), pp. 20-23
Article / Letter to editor
Display more detailsDisplay less details
SubjectDCN 1: Perception and Action; EBP 1: Determinants in Health and Disease; NCEBP 9: Mental health; UMCN 3.2: Cognitive neurosciences
BACKGROUND: The availability of new atypical antipsychotics provides new opportunities for the treatment of borderline personality disorder (BPD). METHODS: Original papers on this topic were sought. Our study reviewed and discussed 14 papers. RESULTS: 2 RCTs, 4 non-controlled open-label studies and 8 case reports. The patient populations studied were highly diverse and the dropout rate after a long follow-up period was high. All of the articles reported positive effects of olanzapine, clozapine, quetiapine and risperidone. CONCLUSION: BPD patients with psychotic-like, impulsive or suicidal symptoms might benefit from atypical antipsychotics. Since the methodological quality of the reviewed articles is poor, further randomised placebo-controlled studies with longer follow-ups are needed before any firm conclusions can be drawn.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.